Opthea Share Price and Company Fundamentals



Price
$1.385
Change
0.005 (0.362%)
52 week
1.377 - 3.6

Last traded: Today at 4:22 AM

Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Key Metrics

PE ratio

-

PB ratio

2.37

Dividend yield

Beta

-0.02

Market cap

$467.66M

Enterprise value

$277.14M

Company profile

Primary activitiesOpthea is a drug development company developing innovative, biologics-based therapies for the treatment of eye disease.
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.opthea.com
Mailing address650 Chapel Street Suite 0403 Level 4 South Yarra VIC 3141 Australia
Phone / Fax61 3 9826 0399 / 61 3 9824 0083
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Opthea does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Opthea.

NameTitleAgeTotal Pay
Dr. Megan Baldwin M.A.I.C.D., Ph.D., MAICDMD, CEO & Exec. Director45591.3k
Mr. Michael Tonroe B.Sc., F.C.A., M.A.I.C.D., Bsc(Hons), ACA, MAICDCFO & Company Sec.53351.56k
Ms. Annie LeeFin. & Operations Mang.
Dr. Richard ChadwickHead of Intellectual Property54
Dr. Michael GeromettaHead of Chemistry, Manufacturing & Controls Devel.56
Dr. Ian LeitchDirector of Clinical Research57
Dr. James GodingIndependent Consultant

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-17,465.95%

Return on assets

-16.98%

Return on equity

-32.37%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Opthea is 467.66M and its enterprise value is 277.14M. The enterprise value to revenue ratio of OPT is 1,214.19.

Companies similar to Opthea (OPT)

Opthea (ASX:OPT) Frequently Asked Questions

1. What is Opthea's Stock Symbol?

Opthea trades on ASX under the ticker symbol "OPT".

2. What is Opthea's stock price today?

One share of OPT stock can currently be purchased for approximately $1.385.

3. How can I contact Opthea?

Opthea's mailing address is 650 Chapel Street Suite 0403 Level 4 South Yarra VIC 3141 Australia. The company can be reached via phone at 61 3 9826 0399.

4. What is Opthea's official website?

The official website of Opthea is http://www.opthea.com.

5. Which share registry manages Opthea's stock?

Opthea's stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.